

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Sheet 2 of 3

ATTORNEY DOCKET No.

3333/1/US

SERIAL No.

10/031,181

APPLICANT

Stallings, et al.

FILING DATE

January 16, 2002

GROUP

Not known 1626

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Purported Publication Date	Country	Class/ Subclass	Translation	
						Yes	No
19	KS	EP 0 780 386 A1	06/25/1997	Europe	C07D 309/08		
20		EP 0 950 656 A1	10/20/1999	Europe	C07C 311/00		
21		JP 11-236369	08/31/1999	Japan	C07C 311/45		x
22	KS	JP 11-246527	09/14/1999	Japan	C07D 213/55		x


OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
23	KS	Reinemer et al., <i>Structural Implications for the role of the N terminus in the 'superactivation' of collagenases</i> , FEBS LETTERS, 338:227-233 (1994).
24		Brünger, <i>Free R value: a novel statistical quantity for assessing the accuracy of crystal structures</i> , NATURE, 355:472-475 (1992).
25		Denis et al., <i>Matrix metalloproteinase inhibitors: Present achievements and future prospects</i> , INVESTIG. NEW DRUGS, 15:175-185 (1997).
26		Gearing et al., <i>Processing of tumour necrosis factor-α precursor by metalloproteinases</i> , NATURE, 370:555-557 (1994).
27		Grams et al., <i>X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors - Implications for substrate binding and rational drug design</i> , EUR. J. BIOCHEM., 228:830-841 (1995).
28		Jones et al., <i>Improved methods for building protein models in electron density maps and the location of errors in these models</i> , ACTA. CRYST., A47:110-119 (1991).
29		Kiyama et al., <i>Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors</i> , J. MED. CHEM., 42:1723-1738 (1999).
30		Lovejoy et al., <i>Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors</i> , NAT. STRUC. BIOL., 6(3):217-221 (1999).
31		McGeehan et al., <i>Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor</i> , NATURE, 370:558-561 (1994).
32		Mitchell et al., <i>Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage</i> , J. CLIN. INVEST., 97(3):761-768 (1996).
33	KS	Morgunova et al., <i>Structure of human pro-matrix metalloproteinase-2: Activation mechanism revealed</i> , SCIENCE, 284:1667-1670 (1999).

Examiner: Kamal Saeed

Date Considered: 09/03/02

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Sheet 3 of 3

ATTORNEY DOCKET No.	SERIAL No.
3333/1/US	10/031,181
APPLICANT	
Stallings, et al.	
FILING DATE	GROUP
January 16, 2002	Not known

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
34	KS	Nicholls et al.; <i>Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons</i> , PROTEINS, 11(4) 281-296 (1991).
35		Otwinowski, <i>Oscillation data reduction program</i> , in PROCEEDINGS OF CCP-4 STUDY WEEKEND: DATA COLLECTION AND PROCESSING, 56-62 (1993).
36		Parks et al., <i>MATRIX METALLOPROTEINASES</i> , 32-33 (1998).
37		Rasmussen et al., <i>Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat</i> , PHARMACOL. THER., 75(1):69-75 (1997).
38		Reboul et al., <i>The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes</i> , J. CLIN. INVEST., 97(9):2011-2019 (1996).
39		Schwartz et al., <i>Synthetic inhibitors of bacterial and mammalian interstitial collagenases</i> , PROG. IN MED. CHEM., 29:271-334 (1992).
40		Tamura et al., <i>Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives</i> , J. MED. CHEM., 41:640-649 (1998).
41	KS	PCT/US00/16323 (WO 01/05389) International Search Report and Transmittal, 9 pgs.

Examiner: Kamal Saeed

Date Considered: 09/03/03

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



#6

FORM HDP-1 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 1 of 3	ATTORNEY DOCKET NO.	SERIAL NO.
	3333/1/US	10/031,181
	APPLICANT	
	Stallings et al.	
	FILING DATE	GROUP
	January 16, 2002	1626

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Purported Publication Date	Name	Class/ Subclass	Purported Filing Date
1	KS	4,595,700	06/17/1986	Donald et al.	514/616	02/21/1985
2	KS	6,362,183	03/26/2002	Freskos et al.	514/238.2	03/04/1997

FOREIGN PATENT DOCUMENTS							
Ref. Desig.	Examiner's Initials	Document Number	Purported Publication Date	Country	Class/ Subclass	Translation	
						Yes	No
3	KS	WO 90/05719	05/31/1990	PCT	C07C 323/62		
4	KS	WO 93/20047	10/14/1993	PCT	C07C 317/44		
5	KS	WO 94/02466	02/03/1994	PCT	C07D 221/14		
6		WO 95/09841	04/13/1995	PCT	C07C 323/60		
7		WO 95/13289	05/11/1995	PCT	A61K 9/127		
8		WO 95/29892	11/09/1995	PCT	C07D 207/327		
9		WO 96/06074	02/29/1996	PCT	C07C 259/06		
10		WO 97/20824	06/12/1997	PCT	C07D 241/04		
11		WO 97/24117	07/10/1997	PCT	A61K 31/19		
12		WO 98/03166	01/29/1998	PCT	A61K 31/18		
13		WO 98/39329	09/11/1998	PCT	C07D 413/12		
14		WO 98/39315	09/11/1998	PCT	C07D 309/08		
15		WO 99/42433	08/26/1999	PCT	C07C 201/08		
16		WO 94/24140	10/27/1994	PCT	C07H 13/04		
17		EP 0 757 037 A2	02/05/1997	Europe	C07C 311/42		
18	KS	EP 0 757 984 A1	02/12/1997	Europe	C07C 311/46		

Examiner: <u>Kamal Saeed</u>	Date Considered: <u>09/03/02</u>
------------------------------	----------------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.